Cambridge Investment Research Advisors, Inc. Beam Therapeutics Inc. Transaction History
Cambridge Investment Research Advisors, Inc.
- $29.4 Billion
- Q3 2024
A detailed history of Cambridge Investment Research Advisors, Inc. transactions in Beam Therapeutics Inc. stock. As of the latest transaction made, Cambridge Investment Research Advisors, Inc. holds 10,435 shares of BEAM stock, worth $263,901. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,435Holding current value
$263,901% of portfolio
0.0%Shares
9 transactions
Others Institutions Holding BEAM
# of Institutions
236Shares Held
75.2MCall Options Held
438KPut Options Held
232K-
Farallon Capital Management LLC San Francisco, CA8.21MShares$208 Million1.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.84MShares$198 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.63MShares$193 Million0.0% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl6.53MShares$165 Million1.52% of portfolio
-
Arch Venture Management, LLC Chicago, IL4.83MShares$122 Million71.21% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.78B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...